Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines

被引:120
作者
Flieger, D [1 ]
Renoth, S [1 ]
Beier, I [1 ]
Sauerbruch, T [1 ]
Schmidt-Wolf, I [1 ]
机构
[1] Univ Bonn, Med Klin & Poliklin 1, D-53105 Bonn, Germany
关键词
ADCC; CDCC; IDEC-C2B8; interleukin-2; rituximab;
D O I
10.1006/cimm.2000.1693
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
With a new flow cytometric cytotoxicity assay, we examined the mechanism of action of chimeric mouse human anti-CD20 monoclonal antibody IDEC-C2B8. IDEC-C2B8 alone induced direct cytotoxicity in four of eight examined CD20-expressing lymphoma cell lines (RAJI, DAUDI, JOK-1, and WT100) at a concentration above 100 ng/ml. Moreover, after 4 h incubation in human serum, only a moderate complement-dependent cellular cytotoxicity (CDCC) was observed, whereas cytotoxicity increased markedly after 3 days of culture, indicating that combined direct cytotoxicity and CDCC were responsible. IDEC-C2B8 induced an effective antibody-dependent cellular cytotoxicity (ADCC) in seven of eight tested lymphoma cell lines when peripheral blood mononuclear cells were used as effector cells. ADCC was moderately enhanced by cytokine interleukin-2, whereas interleukin-12 interferon-alpha, and GM-CSF had no influence. Interestingly, we could demonstrate a correlation between CD32 expression on lymphoma cell lines and IDEC-C2B8-induced direct cytotoxicity, indicating that crosslinking of CD20 with CD32 may be involved in the mechanism of cytotoxicity. We propose that direct cytotoxicity, CDCC, and ADCC result in the marked elimination of CD20-expressing tumor cells observed after treatment with IDEC-C2B8. (C) 2000 Academic Press.
引用
收藏
页码:55 / 63
页数:9
相关论文
共 48 条
  • [1] Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin
    Benoit, NE
    Wade, WF
    [J]. IMMUNOPHARMACOLOGY, 1996, 35 (02): : 129 - 139
  • [2] Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
    Berinstein, NL
    Grillo-Lopez, AJ
    White, CA
    Bence-Bruckler, I
    Maloney, D
    Czuczman, M
    Green, D
    Rosenberg, J
    McLaughlin, P
    Shen, D
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (09) : 995 - 1001
  • [3] BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
  • [4] The combination of interleukin-2 and interferon α effectively augments the antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2 against the colorectal carcinoma cell line HT29
    Bungard, S
    Flieger, D
    Schweitzer, S
    Sauerbruch, T
    Spengler, U
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 46 (04) : 213 - 220
  • [5] ROLE OF THE BP35 CELL-SURFACE POLYPEPTIDE IN HUMAN B-CELL ACTIVATION
    CLARK, EA
    SHU, G
    LEDBETTER, JA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (06) : 1766 - 1770
  • [6] DAVIS T, 1998, P AN M AM SOC CLIN, V17, pA39
  • [7] ASSOCIATION OF 75/80-KDA PHOSPHOPROTEINS AND THE TYROSINE KINASES LYN, FYN, AND LCK WITH THE B-CELL MOLECULE-CD20 - EVIDENCE AGAINST INVOLVEMENT OF THE CYTOPLASMIC REGIONS OF CD20
    DEANS, JP
    KALT, L
    LEDBETTER, JA
    SCHIEVEN, GL
    BOLEN, JB
    JOHNSON, P
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (38) : 22632 - 22638
  • [8] Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment
    Deans, JP
    Robbins, SM
    Polyak, MJ
    Savage, JA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (01) : 344 - 348
  • [9] DEMIDEM A, 1995, FASEB J, V9, pA206
  • [10] FLIEGER D, 1988, CANCER RES, V48, P4812